myLaurel

myLaurel is a New York–based, technology-enabled medical group that delivers hands‑on acute and transitional care in patients’ homes for frail, elderly, and medically complex populations, combining field clinicians, virtual physician oversight, and point‑of‑care diagnostics to reduce hospital use and readmissions[6][2].

High‑level overview

• Mission: myLaurel’s stated mission is to “drive extraordinary care home” by shifting portions of hospital-level acute and transitional care into patients’ homes to improve outcomes and reduce costs for health systems and payers[6][2].[6]
  - Investment / corporate context: myLaurel has raised multiple rounds of growth capital and counts investors including Deerfield Management and GV among backers, reflecting institutional support for its expansion[5][4].[5]
  - Key sectors: myLaurel operates at the intersection of home‑based care delivery, telehealth/virtual care, and clinical operations for health systems and payers[6][2].[6]
  - Impact on the startup/healthcare ecosystem: By demonstrating reduced ED utilization, lower readmission rates, large bed‑day savings, and high patient NPS, myLaurel strengthens the business case for hospital‑at‑home and in‑home acute care models and creates demand for integrated diagnostics, remote monitoring, and field clinical workforce platforms[5][2][6].[5]

Origin story

• Founding and evolution: myLaurel was founded in 2016 as a response to inefficiencies and over‑reliance on facility‑based acute care, and has since evolved into a tech‑enabled medical group scaling acute and transitional care delivered in the home[1][3].[1]
  - Early traction and pivotal moments: The company reported measurable outcomes—such as reductions in ED utilization and readmissions and substantial bed‑day savings—that helped secure notable investors and later growth financings, including a reported $12M initial closing led by Deerfield and GV in 2025[5][6].[5]

Core differentiators

• Hybrid care model: Combines highly trained field responders who deliver hands‑on services in the home with 24/7 virtual physician and nurse support, enabling hospital‑level interventions outside the hospital[2][6].[2]
  - Advanced in‑home diagnostics and therapeutics: Offers point‑of‑care blood tests, EKG, ultrasound, urinalysis, remote patient monitoring, mobile imaging, and in‑home therapeutics such as IV/IM medications, oxygen, fluids, and nebulizers[2].[2]
  - Operational integration with health systems: Uses hospital‑based clinical liaisons and EMR‑integrated algorithms for patient identification and care coordination, easing referrals and at‑risk population management[2].[2]
  - Measured outcomes and ROI: Reports outcomes like 33% lower ED utilization, 49% fewer readmissions, thousands of bed days saved per hospital annually, and high patient NPS, which supports a near‑term ROI proposition for partners[5][6].[5]

Role in the broader tech landscape

• Trend alignment: myLaurel rides the broader “hospital‑at‑home” and care‑anywhere trend driven by capacity strain on hospitals, ageing populations, value‑based payment models, and advances in remote diagnostics and telemedicine[6][2].[6]
  - Why timing matters: Rising hospital capacity constraints and payer interest in lowering costly inpatient utilization create demand for scalable in‑home acute care solutions that can be integrated with system workflows and risk contracts[6][2].[6]
  - Market forces in their favor: Health systems and payers seeking short‑term ROI, reductions in readmissions, and improved patient experience provide receptive customers for myLaurel’s model; concurrent investor interest in care‑at‑home has enabled capital to scale operations[5][6].[5]
  - Ecosystem influence: By operationalizing a hybrid in‑home care model with measurable outcomes, myLaurel increases the viability of field workforces, home diagnostics, and hospital‑system partnerships—encouraging suppliers and competitors to develop complementary technologies and services[2][6].[2]

Quick take & future outlook

• What’s next: myLaurel’s recent financings and reported partner outcomes position it to scale partnerships with health systems and payers, expand geographic coverage, and deepen integration with EMRs and risk contracts to capture more at‑risk cohorts[5][6].[5]
  - Key trends that will shape them: Continued growth in value‑based payment arrangements, improvements in point‑of‑care diagnostics and remote monitoring, workforce availability for in‑home clinicians, and regulatory support for care‑at‑home reimbursement will drive opportunity and constraints for myLaurel[6][2].[6]
  - How influence might evolve: If myLaurel sustains demonstrated cost and quality outcomes at scale, it could become a preferred operational partner for hospitals seeking rapid capacity relief and for payers seeking readmission reduction—further legitimizing hybrid field‑plus‑virtual care as standard practice[5][6].[5]

Quick take: myLaurel packages clinical operations, diagnostics, and virtual oversight into a replicable acute‑care‑at‑home product that has shown measurable system‑level impact, and its near‑term challenge and opportunity are executional scale—growing the field workforce, deepening system integrations, and expanding payer/provider contracts to convert promising pilots into sustained enterprise programs[6][5].[6]